At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
Alisertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas
In Brief
A Phase 1 clinical trial evaluating Alisertib for Advanced Solid Tumors and Lymphoma. Completed, enrolled 26 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of food on the single-dose pharmacokinetics (PK) of alisertib administered as an enteric-coated tablet (ECT) formulation in participants with advanced solid tumors or lymphomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartJul 2013
Primary CompletionMar 2014
Study CompletionJan 2017
TodayJul 2026
First PostedJul 12, 2013
Enrollment StartJul 16, 2013
Primary CompletionMar 5, 2014
Study CompletionJan 24, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.0 years ago
Interventions
Alisertibdrug
Alisertib ECT